Chronic Kidney Disease (CKD) Drugs - Global Market Outlook (2017-2023)

  • ID: 4426136
  • Report
  • Region: Global
  • 160 pages
  • Stratistics Market Research Consulting Pvt Ltd
1 of 4

FEATURED COMPANIES

  • AbbVie, Inc.
  • Allergan plc.
  • Amgen Inc.
  • AstraZeneca plc
  • FibroGen Inc
  • GlaxoSmithKline plc.
  • MORE
The Global Chronic Kidney Disease (CKD) Drugs market is expected to grow from $12.87 billion in 2016 to reach $16.13 billion by 2023 with a CAGR of 3.2%. Drivers that are shaping the global market include, growing incidences of chronic kidney diseases, rise in aged population, rising incidence of diabetes and obesity related disorders, significant unmet requirements and beneficial reimbursement policies. On the other hand, factors such as intense competition from biosimilars and growing preferences of generic drugs are creating a negative impact on the market growth.

By end user, the hospital segment is anticipated to dominate the market globally. North America leads the global market with a largest market share driven by huge acceptance of advanced technological products.

Some of the key players profiled in this market include Hoffmann-La Roche Ltd., GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd., Sanofi S.A., AstraZeneca plc, Pfizer, Inc., Amgen Inc., Kissei Pharmaceutical Co., Ltd, AbbVie, Inc., Keryx Biopharmaceuticals, Inc., Allergan plc., FibroGen Inc and Johnson & Johnson.

End Users Covered:
  • Specialty Clinics
  • Hospitals
Drug Classes Covered:
  • Calcium channel blockers
  • Antihypertensive
  • Anemia Treatment Drugs
  • Antihyperlipidemic
  • Erythropoiesis-stimulating agents (ESAs)
  • Swelling Treatment Drugs
  • Beta blockers
  • Diuretics
  • Angiotensin-II receptor blockers
  • ACE Inhibitors
  • Other Drug Classes
Regions Covered:
  • North America
  • US
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • Italy
  • UK
  • Spain
  • Rest of Europe
  • Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • Rest of Asia Pacific
  • Rest of the World
  • Middle East
  • Brazil
  • Argentina
  • South Africa
  • Egypt
What The Report Offers:
  • Market share assessments for the regional and country level segments
  • Market share analysis of the top industry players
  • Strategic recommendations for the new entrants
  • Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie, Inc.
  • Allergan plc.
  • Amgen Inc.
  • AstraZeneca plc
  • FibroGen Inc
  • GlaxoSmithKline plc.
  • MORE
1. Executive Summary

2. Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions

3. Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 End User Analysis
3.7 Emerging Markets
3.8 Futuristic Market Scenario

4. Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5. Global Chronic Kidney Disease (CKD) Drugs Market, By End User
5.1 Introduction
5.2 Specialty Clinics
5.3 Hospitals

6. Global Chronic Kidney Disease (CKD) Drugs Market, By Drug Class
6.1 Introduction
6.2 Calcium channel blockers
6.3 Antihypertensive
6.4 Anemia Treatment Drugs
6.5 Antihyperlipidemic
6.6 Erythropoiesis-stimulating agents (ESAs)
6.7 Swelling Treatment Drugs
6.8 Beta blockers
6.9 Diuretics
6.10 Angiotensin-II receptor blockers
6.11 ACE Inhibitors
6.12 Other Drug Classes

7. Global Chronic Kidney Disease (CKD) Drugs Market, By Geography
7.1 North America
7.1.1 US
7.1.2 Canada
7.1.3 Mexico
7.2 Europe
7.2.1 Germany
7.2.2 France
7.2.3 Italy
7.2.4 UK
7.2.5 Spain
7.2.6 Rest of Europe
7.3 Asia Pacific
7.3.1 Japan
7.3.2 China
7.3.3 India
7.3.4 Australia
7.3.5 New Zealand
7.3.6 Rest of Asia Pacific
7.4 Rest of the World
7.4.1 Middle East
7.4.2 Brazil
7.4.3 Argentina
7.4.4 South Africa
7.4.5 Egypt

8. Key Developments
8.1 Agreements, Partnerships, Collaborations and Joint Ventures
8.2 Acquisitions & Mergers
8.3 New Product Launch
8.4 Expansions
8.5 Other Key Strategies

9. Company Profiles
9.1 Hoffmann-La Roche Ltd.
9.2 GlaxoSmithKline plc.
9.3 Teva Pharmaceutical Industries Ltd.
9.4 Sanofi S.A.
9.5 AstraZeneca plc
9.6 Pfizer, Inc.
9.7 Amgen Inc.
9.8 Kissei Pharmaceutical Co., Ltd
9.9 AbbVie, Inc.
9.10 Keryx Biopharmaceuticals, Inc.
9.11 Allergan plc.
9.12 FibroGen Inc
9.13 Johnson & Johnson

List of Tables

Table 1 Global Chronic Kidney Disease (CKD) Market Analysis, By Region (2015-2023) ($MN)
Table 2 Global Chronic Kidney Disease (CKD) Market Analysis, By End User (2015-2023) ($MN)
Table 3 Global Chronic Kidney Disease (CKD) Market Analysis, By Specialty Clinics (2015-2023) ($MN)
Table 4 Global Chronic Kidney Disease (CKD) Market Analysis, By Hospitals (2015-2023) ($MN)
Table 5 Global Chronic Kidney Disease (CKD) Market Analysis, By Drug Class (2015-2023) ($MN)
Table 6 Global Chronic Kidney Disease (CKD) Market Analysis, By Calcium channel blockers (2015-2023) ($MN)
Table 7 Global Chronic Kidney Disease (CKD) Market Analysis, By Antihypertensive (2015-2023) ($MN)
Table 8 Global Chronic Kidney Disease (CKD) Market Analysis, By Anemia Treatment Drugs (2015-2023) ($MN)
Table 9 Global Chronic Kidney Disease (CKD) Market Analysis, By Antihyperlipidemic (2015-2023) ($MN)
Table 10 Global Chronic Kidney Disease (CKD) Market Analysis, By Erythropoiesis-stimulating agents (ESAs) (2015-2023) ($MN)
Table 11 Global Chronic Kidney Disease (CKD) Market Analysis, By Swelling Treatment Drugs (2015-2023) ($MN)
Table 12 Global Chronic Kidney Disease (CKD) Market Analysis, By Beta blockers (2015-2023) ($MN)
Table 13 Global Chronic Kidney Disease (CKD) Market Analysis, By Diuretics (2015-2023) ($MN)
Table 14 Global Chronic Kidney Disease (CKD) Market Analysis, By Angiotensin-II receptor blockers (2015-2023) ($MN)
Table 15 Global Chronic Kidney Disease (CKD) Market Analysis, By ACE Inhibitors (2015-2023) ($MN)
Table 16 Global Chronic Kidney Disease (CKD) Market Analysis, By Other Drug Classes (2015-2023) ($MN)
Table 17 North America Chronic Kidney Disease (CKD) Market Analysis, By Country (2015-2023) ($MN)
Table 18 North America Chronic Kidney Disease (CKD) Market Analysis, By End User (2015-2023) ($MN)
Table 19 North America Chronic Kidney Disease (CKD) Market Analysis, By Specialty Clinics (2015-2023) ($MN)
Table 20 North America Chronic Kidney Disease (CKD) Market Analysis, By Hospitals (2015-2023) ($MN)
Table 21 North America Chronic Kidney Disease (CKD) Market Analysis, By Drug Class (2015-2023) ($MN)
Table 22 North America Chronic Kidney Disease (CKD) Market Analysis, By Calcium channel blockers (2015-2023) ($MN)
Table 23 North America Chronic Kidney Disease (CKD) Market Analysis, By Antihypertensive (2015-2023) ($MN)
Table 24 North America Chronic Kidney Disease (CKD) Market Analysis, By Anemia Treatment Drugs (2015-2023) ($MN)
Table 25 North America Chronic Kidney Disease (CKD) Market Analysis, By Antihyperlipidemic (2015-2023) ($MN)
Table 26 North America Chronic Kidney Disease (CKD) Market Analysis, By Erythropoiesis-stimulating agents (ESAs) (2015-2023) ($MN)
Table 27 North America Chronic Kidney Disease (CKD) Market Analysis, By Swelling Treatment Drugs (2015-2023) ($MN)
Table 28 North America Chronic Kidney Disease (CKD) Market Analysis, By Beta blockers (2015-2023) ($MN)
Table 29 North America Chronic Kidney Disease (CKD) Market Analysis, By Diuretics (2015-2023) ($MN)
Table 30 North America Chronic Kidney Disease (CKD) Market Analysis, By Angiotensin-II receptor blockers (2015-2023) ($MN)
Table 31 North America Chronic Kidney Disease (CKD) Market Analysis, By ACE Inhibitors (2015-2023) ($MN)
Table 32 North America Chronic Kidney Disease (CKD) Market Analysis, By Other Drug Classes (2015-2023) ($MN)
Table 33 Europe Chronic Kidney Disease (CKD) Market Analysis, By Country (2015-2023) ($MN)
Table 34 Europe Chronic Kidney Disease (CKD) Market Analysis, By End User (2015-2023) ($MN)
Table 35 Europe Chronic Kidney Disease (CKD) Market Analysis, By Specialty Clinics (2015-2023) ($MN)
Table 36 Europe Chronic Kidney Disease (CKD) Market Analysis, By Hospitals (2015-2023) ($MN)
Table 37 Europe Chronic Kidney Disease (CKD) Market Analysis, By Drug Class (2015-2023) ($MN)
Table 38 Europe Chronic Kidney Disease (CKD) Market Analysis, By Calcium channel blockers (2015-2023) ($MN)
Table 39 Europe Chronic Kidney Disease (CKD) Market Analysis, By Antihypertensive (2015-2023) ($MN)
Table 40 Europe Chronic Kidney Disease (CKD) Market Analysis, By Anemia Treatment Drugs (2015-2023) ($MN)
Table 41 Europe Chronic Kidney Disease (CKD) Market Analysis, By Antihyperlipidemic (2015-2023) ($MN)
Table 42 Europe Chronic Kidney Disease (CKD) Market Analysis, By Erythropoiesis-stimulating agents (ESAs) (2015-2023) ($MN)
Table 43 Europe Chronic Kidney Disease (CKD) Market Analysis, By Swelling Treatment Drugs (2015-2023) ($MN)
Table 44 Europe Chronic Kidney Disease (CKD) Market Analysis, By Beta blockers (2015-2023) ($MN)
Table 45 Europe Chronic Kidney Disease (CKD) Market Analysis, By Diuretics (2015-2023) ($MN)
Table 46 Europe Chronic Kidney Disease (CKD) Market Analysis, By Angiotensin-II receptor blockers (2015-2023) ($MN)
Table 47 Europe Chronic Kidney Disease (CKD) Market Analysis, By ACE Inhibitors (2015-2023) ($MN)
Table 48 Europe Chronic Kidney Disease (CKD) Market Analysis, By Other Drug Classes (2015-2023) ($MN)
Table 49 Asia Pacific Chronic Kidney Disease (CKD) Market Analysis, By Country (2015-2023) ($MN)
Table 50 Asia Pacific Chronic Kidney Disease (CKD) Market Analysis, By End User (2015-2023) ($MN)
Table 51 Asia Pacific Chronic Kidney Disease (CKD) Market Analysis, By Specialty Clinics (2015-2023) ($MN)
Table 52 Asia Pacific Chronic Kidney Disease (CKD) Market Analysis, By Hospitals (2015-2023) ($MN)
Table 53 Asia Pacific Chronic Kidney Disease (CKD) Market Analysis, By Drug Class (2015-2023) ($MN)
Table 54 Asia Pacific Chronic Kidney Disease (CKD) Market Analysis, By Calcium channel blockers (2015-2023) ($MN)
Table 55 Asia Pacific Chronic Kidney Disease (CKD) Market Analysis, By Antihypertensive (2015-2023) ($MN)
Table 56 Asia Pacific Chronic Kidney Disease (CKD) Market Analysis, By Anemia Treatment Drugs (2015-2023) ($MN)
Table 57 Asia Pacific Chronic Kidney Disease (CKD) Market Analysis, By Antihyperlipidemic (2015-2023) ($MN)
Table 58 Asia Pacific Chronic Kidney Disease (CKD) Market Analysis, By Erythropoiesis-stimulating agents (ESAs) (2015-2023) ($MN)
Table 59 Asia Pacific Chronic Kidney Disease (CKD) Market Analysis, By Swelling Treatment Drugs (2015-2023) ($MN)
Table 60 Asia Pacific Chronic Kidney Disease (CKD) Market Analysis, By Beta blockers (2015-2023) ($MN)
Table 61 Asia Pacific Chronic Kidney Disease (CKD) Market Analysis, By Diuretics (2015-2023) ($MN)
Table 62 Asia Pacific Chronic Kidney Disease (CKD) Market Analysis, By Angiotensin-II receptor blockers (2015-2023) ($MN)
Table 63 Asia Pacific Chronic Kidney Disease (CKD) Market Analysis, By ACE Inhibitors (2015-2023) ($MN)
Table 64 Asia Pacific Chronic Kidney Disease (CKD) Market Analysis, By Other Drug Classes (2015-2023) ($MN)
Table 65 RoW Chronic Kidney Disease (CKD) Market Analysis, By Country (2015-2023) ($MN)
Table 66 RoW Chronic Kidney Disease (CKD) Market Analysis, By End User (2015-2023) ($MN)
Table 67 RoW Chronic Kidney Disease (CKD) Market Analysis, By Specialty Clinics (2015-2023) ($MN)
Table 68 RoW Chronic Kidney Disease (CKD) Market Analysis, By Hospitals (2015-2023) ($MN)
Table 69 RoW Chronic Kidney Disease (CKD) Market Analysis, By Drug Class (2015-2023) ($MN)
Table 70 RoW Chronic Kidney Disease (CKD) Market Analysis, By Calcium channel blockers (2015-2023) ($MN)
Table 71 RoW Chronic Kidney Disease (CKD) Market Analysis, By Antihypertensive (2015-2023) ($MN)
Table 72 RoW Chronic Kidney Disease (CKD) Market Analysis, By Anemia Treatment Drugs (2015-2023) ($MN)
Table 73 RoW Chronic Kidney Disease (CKD) Market Analysis, By Antihyperlipidemic (2015-2023) ($MN)
Table 74 RoW Chronic Kidney Disease (CKD) Market Analysis, By Erythropoiesis-stimulating agents (ESAs) (2015-2023) ($MN)
Table 75 RoW Chronic Kidney Disease (CKD) Market Analysis, By Swelling Treatment Drugs (2015-2023) ($MN)
Table 76 RoW Chronic Kidney Disease (CKD) Market Analysis, By Beta blockers (2015-2023) ($MN)
Table 77 RoW Chronic Kidney Disease (CKD) Market Analysis, By Diuretics (2015-2023) ($MN)
Table 78 RoW Chronic Kidney Disease (CKD) Market Analysis, By Angiotensin-II receptor blockers (2015-2023) ($MN)
Table 79 RoW Chronic Kidney Disease (CKD) Market Analysis, By ACE Inhibitors (2015-2023) ($MN)
Table 80 RoW Chronic Kidney Disease (CKD) Market Analysis, By Other Drug Classes (2015-2023) ($MN)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi S.A.
  • AstraZeneca plc
  • Pfizer, Inc.
  • Amgen Inc.
  • Kissei Pharmaceutical Co., Ltd
  • AbbVie, Inc.
  • Keryx Biopharmaceuticals, Inc.
  • Allergan plc.
  • FibroGen Inc
  • Johnson & Johnson
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll